baber/WOPTO huggingface dataset:
Patent ES-2315472-T3 (ES)
Inventor: JANNETEAU CHRISTOPHE
IPC: H04L45/16
Filed: 2003-12-23
Granted: 2009-04-01
Abstract: A method of communicating traffic from a source to a group (G) of nodes including a Network Node (MNN) in a network using one or more multicast protocols. The network also comprises a Router (MR) for forwarding traffic between the network and the Internet and a Multicast Signalling Gateway (MSG) co-located with the Router (MR) and translating on an interface signalling messages of a multicast routing protocol (MRP) into messages of a group membership protocol (GMP). In the case of mobile networks, the interface is preferably an egress interface of the Mobile Router (MR). The Multicast Signalling Gateway (MSG) preferably translates multicast packets together with unicast source addresses and multicast destination addresses of multicast packets between IPv4 and IPv6 protocols. <IMAGE>
Patent ES-2342269-T3 (ES)
Inventor: KOVACIC PETER
IPC: B26D7/01
Filed: 2003-02-21
Granted: 2010-07-05
Abstract: A universal slicer contains a housing, a rotatably mounted revolving blade, a positioning plate which is provided with a bearing surface for a product that is to be sliced, and a mechanism regulating the width of cut by adjusting the positioning plate in relation to the revolving blade. In order to ensure that the slices are cut in a uniform manner, particularly when using universal slicers that have a simple configuration and are inexpensive to produce, the universal slicer is provided with a tensioning device, by which the positioning plate can be prestressed free from play counter to the mechanism regulating the width of cut.
Patent ES-2291626-T3 (ES)
Inventor: LANCASTER JOANNE SLOAN
IPC: A61P25/00
Filed: 2003-03-12
Granted: 2008-03-01
Abstract: Human antibodies, preferably recombinant human antibodies that specifically bind to human Fas Ligand (hFasL) are disclosed. These antibodies have high affinity for hFasL, a slow off rate for hFasL dissociation and neutralize a Fas Ligand activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antigen-binding portions, of the invention are useful for neutralizing Fas Ligand activity, e.g., in a human subject suffering from a disorder in which hFas Ligand activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant anti-hFasL human antibodies, and the methods for synthesizing the recombinant human antibodies are also encompassed by the invention.
Patent ES-2291663-T3 (ES)
Title: Un metodo para proporcionar un material de envasado con informacion, asi como material de envasado que porta esta informacion.
Inventor: SCHAEDEL BERTIL
IPC: B31B50/88
Filed: 2003-10-03
Granted: 2008-03-01
Abstract: Un método para proporcionar un material de envasado con información desde una instalación para la producción de material de envasado, que comprende las operaciones de: producir una banda (1) de material de envasado, medir (12), en la producción de la banda (1), una magnitud predeterminada (11) en una primera parte (15c) de la banda (1), estando destinada dicha parte (15c) a formar un primer envase, proporcionar, en la producción de la banda (1), una segunda parte (15a) que está destinada a formar un segundo envase, con información 811) relativa a dicha magnitud medida.
Patent ES-2334221-T3 (ES)
Inventor: SHIBUYA KIMIYUKI
IPC: C07D235/28
Filed: 2003-11-27
Granted: 2010-03-08
Abstract: This invention relates to a method for producing 1-Ä2-(benzimidazol-2-ylthio)ethylÜpiperadine (5) or its salt by the following reaction scheme: <CHEM> <??>This invention enables efficient production of 1-Ä2-(benzimidazol-2-ylthio)ethylÜpiperadine or its salt which is an intermediate in the production of a cyclic diamine compound which is useful as a ACAT inhibitor.
Patent ES-2315563-T3 (ES)
Inventor: BECKER WOLFGANG
IPC: F41A7/06
Filed: 2003-08-12
Granted: 2009-04-01
Abstract: A device for controlling an automatic weapon is provided. Disposed on or in a housing detachably mounted on the weapon is an electric drive motor, controlled by an electric control device, that drives a threaded spindle having a spindle nut on which is disposed a driver. A cocking bolt is guided on the housing and is coupled with a safety catch of the weapon, and is disposed in the path of movement of the driver and is movable out of a starting position, counter to the spring force acting on a safety catch, back to a cocking position in an end position of the spindle nut. In the cocking position, the cocking bolt is arrested by an arresting lever in the end position of the spindle nut, corresponding to the safety condition of the weapon. The cocking bolt is released by the spindle nut during its advancement in the starting position thereof, which corresponds to the released safety catch position of the weapon and leads to advancement of the cocking bolt and safety catch.
Patent ES-2335988-T3 (ES)
Inventor: DUA BHUPESH
IPC: A43B1/14
Filed: 2003-12-15
Granted: 2010-04-07
Abstract: The invention is an upper for an article of footwear that includes a textile having fusible filaments or fibers. The textile is incorporated into the upper and specific areas of the upper are heated such that the fusible filaments or fibers fuse with other filaments or fibers to form fused areas. In comparison with unfused areas of the upper, the fused areas may impart properties that include greater stretch-resistance, stability, support, abrasion-resistance, durability, and stiffness, for example. In addition, the fused areas generally provide air-permeability without significantly increasing the weight of the footwear.
Patent ES-2314334-T3 (ES)
Inventor: GERVASE BARBARA A
IPC: C07K14/18
Filed: 1991-11-07
Granted: 2009-03-16
Abstract: The following are claimed: (A) an isolated hepatitis C virus (HCV) a sialoglycoprotein (AG) selected from E1 and E2; (B) a method for purifying HCV AGs, which comprises (a) contacting a compsn. contg. HCV AGs with a mannose-binding protein, e.g. concanavalin A (ConA) or Galanthus nivalus agglutinin (GNA) and (b) isolating the portion of the compsn. which binds to the mannose-binding protein, e.g. by elution with mannose; (c) an assay kit for detecting the presence of HCV AGs, comprising (a) a solid support, (b) a mannose-binding protein, and (c) an antibody specific for the HCV AG, where one of the antibody and the mannose-binding protein is bound to the solid support; (D) a method for determining exposure to or infection by HCV, in which any HCV in a sample of body fluid is concd. by contact with a mannose-binding protein prior to assay; (E) a cell transformed with a vector for recombinant expression of a HCV AG, where the vector comprises a structural gene encoding a glycosoylation signal, a HCV AG, a regulatory sequence operable in the host cell and capable of regulating expressio fo the HCV AG, and a selectable marker, where the cell does not sialylate glycoproteins; and (F) a method for reducing or eliminatng the presence of HCV in plasma, serum or other biological liquids.
Patent ES-2335761-T3 (ES)
Inventor: TARASINSKI NICOLAI DR
IPC: B60W10/10
Filed: 2004-03-31
Granted: 2010-04-05
Abstract: Vehicle drive system, especially for an agricultural or industrial tractor has an arrangement for detecting a gear change or shift command and a control unit that automatically loads a first wheel (12), driven by a first drive motor (18), more highly, controls the changing of the shift gearbox (34) of the second wheel (16) and reduces the load of the drive motor of the first wheel.
Patent ES-2401961-T3 (ES)
Title: Lavadora y método para controlar la misma
Inventor: SON KWEON
IPC: D06F35/00
Filed: 2004-11-19
Granted: 2013-04-25
Abstract: Un método para controlar una lavadora que tiene un tambor (a) con una velocidad de giro ajustable, quecomprende: una primera etapa de hacer girar el tambor a una primera velocidad de giro establecida en una unidad (103)de control; una segunda etapa (S2) de detección de si se produce o no resonancia del tambor a la primera velocidad degiro; una tercera etapa (S3) de cambio de la velocidad de giro del tambor si se detecta resonancia; caracterizado por que cuando se detecta resonancia, la tercera etapa incluye además medir (S5, S6) un excentricidad de la ropacontenida en el tambor girando a la velocidad de giro cambiada.
Patent ES-2308128-T3 (ES)
Inventor: BRUN MICHEL
IPC: B60B19/10
Filed: 2004-11-18
Granted: 2008-12-01
Abstract: The device has blades (3) integrated with a tapered ring (31) to form a crown (30) whose symmetrical axis is merged with the rotational axis of a wheel. Inner surface (311) of the ring cooperates with the blades and with the surface of a rim (2), to create a centrifugal fan directing air flow outside the device. A plate (4) includes surface identical to that of the rim.
Patent ES-2428892-T3 (ES)
Title: Regeneración y neogénesis de célula visual de la retina con el gen Otx2
Inventor: FURUKAWA TAKAHISA
IPC: C12Q1/02
Filed: 2004-02-02
Granted: 2013-11-12
Abstract: Uso de un agente que comprende una proteína Otx2 o una sal de la misma para la inducción de la diferenciación enuna célula fotorreceptora de la retina ex vivo, en el que la proteína es Otx2 (1) una proteína que comprende la secuencia de aminoácidos representada por la SEC ID Nº: 1, la SEC ID Nº: 3 ola SEC ID Nº: 5; o (2) una proteína que consiste en (i) una secuencia de aminoácidos en la que se suprime 1 aminoácido en la secuencia de aminoácidosrepresentada por la SEC ID Nº: 1, la SEC ID Nº: 3 o la SEC ID Nº: 5, (ii) una secuencia de aminoácidos en la que se añade 1 aminoácido a la secuencia de aminoácidosrepresentada por la SEC ID Nº: 1, la SEC ID Nº: 3 o la SEC ID Nº: 5, o (iii) una secuencia de aminoácidos en la que 1 aminoácido en la secuencia de aminoácidos representadapor la SEC ID Nº: 1, la SEC ID Nº: 3 o la SEC ID Nº: 5 es sustituido con otro aminoácido,y que tiene una acción inductora de diferenciación en una célula fotorreceptora de la retina.
Patent ES-2267054-T3 (ES)
Inventor: REYNOLDS BRIAN R
IPC: A61L31/02
Filed: 2004-02-24
Granted: 2007-03-01
Abstract: Alternative designs, materials and manufacturing methods for medical devices. Some embodiments pertain to a composite medical device including an first section having an end, and a connector member defining an opening therein, wherein the end of the elongated section extends into the opening. A bismuth alloy connector material is disposed within the opening, and the connector material is configured to expand when solidified to exert a compressive force within the connector member.
Patent ES-2304608-T3 (ES)
Inventor: KASIELKE JOACHIM
IPC: G01N27/416
Filed: 2004-03-13
Granted: 2008-10-16
Abstract: Biosensor system and method for the electrochemical determination of an analyte in a sample. An analyte reactant is mixed with the sample to form a reaction liquid which is contacted to electrodes for measurement of an analyte detection current. The analyte detection current is characteristic of the analyte concentration in the sample by virtue of a reaction sequence comprising an analyte specific reaction taking place in the reaction liquid and an electrode reaction including transfer of electrons through an electrode surface. A plurality of values of a curve of the analyte detection current versus time is measured and the analyte concentration is derived therefrom by means of an evaluation algorithm. <??>Fast results of high accuracy are achieved in that the DC-voltage is applied to the electrodes during the analyte-specific reaction whereby the analyte-specific reaction and the electrode reaction take place simultaneously resulting in an analyte detection current versus time curve which comprises a section in which the current rises versus time and the analyte detection current is measured at at least two points of time in the rising section and the values of the analyte detection current resulting from said at least two measurements are used in the evaluation algorithm for temperature error compensation. <IMAGE>
Patent ES-2339021-T3 (ES)
Inventor: SALVATI PATRICIA
IPC: A61K31/165
Filed: 2004-04-22
Granted: 2010-05-14
Abstract: Methods of using certain a-aminoamide derivatives as anti-inflammatory agents. The anti-inflammatory agents of the invention are able to reduce or even stop inflammatory s conditions substantially without side effects.
Patent ES-2276307-T3 (ES)
Inventor: BORTHWICK ALAN DAVID
IPC: A61K31/4025
Filed: 2004-06-17
Granted: 2007-06-16
Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.
Patent ES-2323871-T3 (ES)
Inventor: DAVIS TRENT W
IPC: D21F1/00
Filed: 2004-04-07
Granted: 2009-07-27
Abstract: A method whereby a water permeable press fabric is given greater dewatering and drainage capacity by providing voids which are reservoirs of minimum pressure available to accept water.
Patent ES-2270387-T3 (ES)
Inventor: TONCELLI DARIO
IPC: B29C70/02
Filed: 2004-09-09
Granted: 2007-04-01
Abstract: "Bretonstone" technology is used for the production of a dual-layer slab or board-like article. The rear layer is formed from a mix comprising an inorganic granular material in expanded form, in particular consisting of beads of expanded glass, expanded day and the like, a filler in the form of a fine powder, preferably cristobalite, and a hardening resin, in particular epoxy resin or polyester. The first layer, which is intended to form the visible side of the article, comprises the same resin or a resin compatible with that present in said rear layer. A web of continuous glass filaments is arranged between the said two layers. The invention also relates to the article or slab which can be obtained by the abovementioned method.
Patent ES-2320133-T3 (ES)
Inventor: WIEGERINCK MARTINUS ANTONIUS HERMANUS MARIA
IPC: A61B10/00
Filed: 2004-09-23
Granted: 2009-05-19
Abstract: Sampler for self-sampling of samples from a body cavity, such as cervical samples. Optimum accessibility of the cervix is achieved through the sampler comprising a rigid plastic tube which is rounded at the front side. During its introduction, the sampler can accurately be moved to the cervix. The sampler is surrounded by the vagina and can prevent leakage of flushing liquid, and it is possible to use a relatively small quantity of flushing liquid while producing a sample with a high concentration of cervical cells. It is possible to reach the sampling location in a simple and more accurate way which does not damage tissue. As a result of the tube simultaneously being designed as a cylinder for a plunger, it is possible, to flush the desired location with a solution using a cylinder-plunger and, to take the sample by drawing the plunger back.
Patent ES-2309566-T3 (ES)
Inventor: HASENFUSS PETER
IPC: B61B5/02
Filed: 2004-09-30
Granted: 2008-12-16
Abstract: A fully automatic traffic system includes insertable individual system vehicles that are used for transporting persons and goods, are provided with their own drive system, their own steering mechanism, and at least one power take-off and guiding apparatus, and move along a route which encompasses a solid ground forming the running surfaces for the wheels of the individual vehicles, and a power supply and guiding system over which the wheels of the vehicles can roll. At least one power take-off and guiding apparatus of the individual vehicles can be deployed into and retracted from the effective range of the power supply and guiding system of the route. The ground that supports the running surfaces for the wheels of the individual vehicles consists of roadway elements which can be separately arranged and/or laid.
Patent ES-2303108-T3 (ES)
Inventor: DARRAS GILLES
IPC: H05B41/392
Filed: 2004-10-19
Granted: 2008-08-01
Abstract: A ballast for fluorescent tubes and the use thereof for producing fluorescent tube lighting fixtures using a novel gas excitation mode in which light is generated by means of controlled pulses leading to an increased power efficiency, with a data collection and transmission functionality, are disclosed.
Patent ES-2393105-T3 (ES)
Title: Procedimiento de isomerización de un ciclohexenil alquilo o una alquenil cetona
Inventor: JACOBY DENIS
IPC: B01J23/46
Filed: 2004-11-30
Granted: 2012-12-18
Abstract: Un procedimiento para la isomerización de un sustrato de fórmulaen la que cada R1 representa, de forma simultánea o independiente, un átomo de hidrogeno o un grupo metilo y R2representa un grupo alquilo C1-4 o 1-alquenilo C2-5 lineal o ramificado con un átomo de hidrógeno;en una mezcla que comprende al menos un compuesto de fórmula (II) y al menos un compuesto de fórmula (II')en las que R1 y R2 tienen el mismo significado que el indicado anteriormente;llevándose a cabo dicho procedimiento en un medio no coordinante o débilmente coordinante, con una atmósferainerte y en presencia de un catalizador que se puede obtener mediante la reacción dea) un precursor de rutenio de la fórmula [Ru(dieno)(alilo)2], [Ru(dienilo)2], [Ru(tetraeno)(eno)] o [Ru(dieno)(trieno)]; yb) un ácido prótico de fórmula HX; oun ácido de Lewis de fórmula B(R3)3, en la que R3 representa un grupo fluoruro o fenilo opcionalmente sustituidopor de uno a cinco grupos tales como átomos de haluro o grupos metilo o CF3, o un ácido de Lewis de fórmulaFeX3, FeX2, AgX, AlY3, FeY3, FeY2, SnY2, SnY4, AgY, AgY2, SbY5, AsY5 o PY5; siendo X un ClO4-, R4SO3-, en laque R4 es un átomo de cloro o flúor o un grupo fluoroalquilo o fluoroarilo C1-C8, BF4-, PF6-, SbCl6-, AsCl6-, SbF6-,AsF6- o BR4-, en la que R es un grupo fenilo opcionalmente sustituido por uno a cinco grupos tales como átomosde haluro o grupos metilo o CF3 y siendo Y un átomo de flúor o cloro;en un medio no coordinante o débilmente coordinante y en una atmósfera inerte, estando comprendida la relaciónmolar de ácido/rutenio entre 0,3 y 3,1, siendo dicho medio no coordinante o débilmente coordinante un hidrocarburoclorado, hidrocarburo saturado o insaturado, un éter, un éster, un ácido carboxílico o un sustrato de fórmula (I), talcomo se define en la reivindicación 1, o una de sus mezclas
Patent ES-2341777-T3 (ES)
Inventor: DUNN RICHARD L
IPC: A61K9/42
Filed: 2001-09-21
Granted: 2010-06-28
Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate. The present invention is also directed to a method for forming the flowable composition. The present invention is also directed to a biodegradable implant formed in situ, in a patient. The biodegradable implant is formed by injecting a flowable composition within the body of the patient and allowing the biocompatible polar aprotic solvent to dissipate to produce a solid biodegradable implant. The present invention is also directed to a method of forming a biodegradable implant in situ, in a living patient. The method includes injecting a flowable composition within the body of a patient and allowing the biocompatible polar aprotic solvent to dissipate to produce a solid biodegradable implant. The present invention is also directed to a method of treating cancer in a patient. The method includes administering to the patient in need of such treatment an effective amount of a flowable composition of the present invention. The present invention is also directed to a method of reducing LHRH levels in a patient. The method includes administering to the patient in need of such LHRH reduction an effective amount of a flowable composition of the present invention. The present invention is also directed to a kit. The kit includes a first container and a second container. The first container includes a composition that includes a biodegradable thermoplastic polyester and a biocompatible polar aprotic solvent. The second container includes leuprolide acetate. The present invention is also directed to a solid implant. The solid implant includes a biocompatible thermoplastic polyester and leuprolide acetate. The solid implant has a solid or gelatinous microporous matrix, wherein the matrix is a core surrounded by a skin. The solid implant can further include a biocompatible organic solvent.
Patent ES-2326123-T3 (ES)
Title: Parte de recepcion para conectar un vastago de un elemento de anclaje oseo con una barra y dispositivo de anclaje oseo con tal parte de recepcion.
Inventor: MATTHIS WILFRIED
IPC: A61B17/70
Filed: 2005-05-27
Granted: 2009-10-01
Abstract: Dispositivo de anclaje óseo que comprende una parte de recepción (1) para conectar un vástago de un elemento de anclaje óseo a una barra, una barra (7) y un elemento de fijación (10), parte de recepción (1) que comprende: un primer extremo (2) y un segundo extremo (3), un hueco (4) con una sección transversal sustancialmente en forma de U, extendiéndose dicho hueco (4) desde el primer extremo (2) en la dirección del segundo extremo (3) formando dos patas (5, 6) abiertas en el primer extremo (2), definiendo dicho hueco (4) un canal para recibir dicha barra (7), y teniendo dicho canal un eje longitudinal (L), teniendo dichas patas (5, 6) una rosca interna (9) para recibir el elemento de fijación (10) que tiene una rosca externa que coopera con dicha rosca interna para asegurar la barra, y en donde la parte de recepción (1) se puede conectar poliaxialmente con el elemento de anclaje óseo y tiene un taladro (20) que se extiende desde el primer extremo (2) hasta el segundo extremo (3) para ser atravesado por el vástago del elemento de anclaje óseo, teniendo el taladro un eje central (M), proporcionándose un elemento de presión (25) que se puede deslizar por el taladro (20) ejerciendo presión sobre la cabeza del elemento de anclaje óseo para asegurar el elemento de anclaje óseo en posición angular con respecto a la parte de recepción, caracterizado porque dichas patas (5, 6) están provistas de estructuras de refuerzo (11, 12, 15, 11'', 12'', 15'', 115) formadas por un mayor grosor de pared (D) de los bordes externos de dichas patas (5, 6) que es mayor que el grosor de pared (d) de dichas patas (5, 6) que están cerca del eje central (M) del taladro, medido el grosor de pared radialmente con respecto al eje central (M), y en donde el mayor grosor de pared (D) está a la altura del eje longitudinal de la barra cuando la barra se inserta en la parte de recepción, colocándose las estructuras de refuerzo en partes inclinadas cuyo grosor de pared disminuye hacia el primer extremo (2) de la parte de recepción.